Verrica Pharmaceuticals Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
VRCA Nasdaq 2830 www.verrica.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts - Jun 22nd, 2026 6:05 am
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - May 28th, 2026 6:05 am
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - May 13th, 2026 6:00 am
Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call - May 13th, 2026 3:16 am
Verrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... - May 12th, 2026 11:01 pm
Verrica Pharmaceuticals Q1 Earnings Call Highlights - May 12th, 2026 9:07 pm
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates - May 12th, 2026 3:15 pm
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results - May 12th, 2026 2:01 pm
Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates - May 7th, 2026 1:15 pm
NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA - May 6th, 2026 6:35 am
Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates - May 5th, 2026 3:15 pm
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting - May 5th, 2026 2:05 pm
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026 - May 5th, 2026 6:00 am
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting - Apr 9th, 2026 2:05 pm
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference - Apr 6th, 2026 6:00 am
Verrica Pharmaceuticals Inc (VRCA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... - Mar 11th, 2026 1:01 pm
Verrica Pharmaceuticals Q4 Earnings Call Highlights - Mar 11th, 2026 11:01 am
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - Mar 11th, 2026 6:00 am
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 - Mar 5th, 2026 6:00 am
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference - Feb 23rd, 2026 6:00 am